Burden of C. difficile Infection: Clinical Burden

Posted on by microbiomestg

Clinical Burden

CLINICAL BURDEN OF C. DIFF INFECTION

A VICIOUS CYCLE OF RECURRENCE WITH A SIGNIFICANT BURDEN1,2

Significant complications associated with CDI

Recurrence:

Up to 35%3,4,a

Re-recurrence

Up to 60%5-9

Sepsis

27%10,b

Colectomy

7%10,b

Heart Failure

43%9

Mortality

6%3
Virus

Mortality in patients with COVID-19 and CDI: 44%8

Virus

Financial Burden

RECURRENT C. DIFF INFECTION BURDEN

RECURRENT CDI (RCDI) AFFECTS PATIENT QUALITY OF LIFE AND
HOSPITAL QUALITY METRICS AND REIMBURSEMENT

  • Up to 85% of all patients with rCDI were hospitalized in 12 months12
  • 57% of patients with at least one CDI recurrence experienced ≥2 admissions with 12 months9
  • Hospitalizations average 18 days for patients with rCDI9
  • 84% of patients with rCDI are readmitted12
  • −$3K to −$29K gap exists in reimbursement per patient13
  • $131K to $207K comprised total cost of patient with rCDI13

Physical/Psychological Burden

PHYSICAL/PSYCHOLOGICAL RECURRENT C. DIFF INFECTION BURDEN

THE PHYSICAL AND PSYCHOLOGICAL IMPACT OF RECURRENT CDI IS HIGH15

In an observational, cross-sectional study surveying 350 self-reported patients with CDI15

Person holding head

~41%

believed they would never get rid of post-CDI symptoms

Used with permission from Creative Commons. https://creativecommons.org/licenses/by/4.0/legalcode.15

aWithin 8 weeks after initial C. difficile infection diagnosis.
bFirst recurrence.

References: 1. Centers for Disease Control and Prevention. https://www.cdc.gov/drugresistance/pdf/threats-report/clostridioides-difficile-508.pdf. Accessed June 24, 2020. 2. Feuerstadt P, et al. J Med Econ. 2020;23(6):603-609. 3. Lessa FC, et al. N Engl J Med. 2015;372(9):825-834. 4. Cornely OA, et al. Clin Infect Dis. 2012;55(suppl 2):s154-s161. 5. Leong C, Zelenitsky S. Can J Hosp Pharm. 2013;66(6):361-368. 6. Kelly CP. Clin Microbiol Infect. 2012;18(suppl 6):21-27. 7. Riddle DJ, et al. Infect Dis. Clin North Am. 2009;23(3):727-743. 8. Smits WK, et al. a Nat Rev Dis Primers. 2016;2(16020);1-47. 9. Nelson WW, et al. [published online March 11, 2021]. J Manag Care Spec Pharm. 2021;1-11. doi:10.18553/jmcp.2021.20395. 10. Feuerstadt P, et al. SAGE Open Med. 2021;9:2050312120986733. doi:10.1177/2050312120986733. 11. Sandhu A. et al. Emerg Infect Dis. 2020;26(9)2272-2274. 12. Rodrigues R, et al. Infect Control Hosp Epidemiol. 2017;38(2):196-202. 13. McDonald LC, et al. Clin Infect Dis. 2018;66(7):e1-e48. 14. Zilberberg MD, et al. Medicine. 2018;97(36):e12212. doi:10.1097/MD.0000000000012212. 15. Lurienne L, et al. J Patient Rep Outcomes. 2020;4(1):14.